112 related articles for article (PubMed ID: 19502051)
1. Molecular markers of chemotherapy in advanced colorectal cancer: back to square one.
Sobrero A
Eur J Cancer; 2009 Jul; 45(11):1902-3. PubMed ID: 19502051
[No Abstract] [Full Text] [Related]
2. Molecular markers of chemotherapeutic response and toxicity in colorectal cancer.
Braun MS; Quirke P; Seymour MT
Expert Rev Anticancer Ther; 2007 Apr; 7(4):489-501. PubMed ID: 17428170
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetics in chemotherapy of colorectal cancer.
Henriette Tanja L; Guchelaar HJ; Gelderblom H
Best Pract Res Clin Gastroenterol; 2009; 23(2):257-73. PubMed ID: 19414151
[TBL] [Abstract][Full Text] [Related]
4. Recent developments on the integration of biologic agents with cytotoxic chemotherapy in the treatment of advanced colorectal cancer.
Chu E
Clin Colorectal Cancer; 2008 Dec; 7 Suppl 2():S46. PubMed ID: 19064405
[No Abstract] [Full Text] [Related]
5. [Tailored treatment to patients with metastatic colorectal cancer].
Pfeiffer P; Qvortrup C; Hansen TP
Ugeskr Laeger; 2009 Mar; 171(13):1098. PubMed ID: 19321093
[No Abstract] [Full Text] [Related]
6. Genotype-phenotype map and molecular networks: a promising solution in overcoming colorectal cancer resistance to targeted treatment.
Roukos DH; Katsios C; Liakakos T
Expert Rev Mol Diagn; 2010 Jul; 10(5):541-5. PubMed ID: 20629500
[No Abstract] [Full Text] [Related]
7. [Biomarker for chemotherapy in patients with colorectal cancer].
Matsusaka S
Gan To Kagaku Ryoho; 2009 Jan; 36(1):11-4. PubMed ID: 19151559
[TBL] [Abstract][Full Text] [Related]
8. Drug resistance, predictive markers and pharmacogenomics in colorectal cancer.
Longley DB; Allen WL; Johnston PG
Biochim Biophys Acta; 2006 Dec; 1766(2):184-96. PubMed ID: 16973289
[TBL] [Abstract][Full Text] [Related]
9. [Mutation of HSP110 in colorectal cancer: the chaperone paradox].
Garrido C; Collura A; Berthenet K; Lagrange A; Duval A
Med Sci (Paris); 2012 Jan; 28(1):9-10. PubMed ID: 22289816
[No Abstract] [Full Text] [Related]
10. [DNA mismatch genes in colorectal cancer].
Ono H; Inazawa J
Nihon Rinsho; 2011 Apr; 69 Suppl 3():77-83. PubMed ID: 22213935
[No Abstract] [Full Text] [Related]
11. Colorectal cancer therapeutics and the challenges of applied pharmacogenomics.
Kruzelock RP; Short W
Curr Probl Cancer; 2007; 31(5):315-66. PubMed ID: 17905192
[No Abstract] [Full Text] [Related]
12. Genetic variants as potential predictive biomarkers in advanced colorectal cancer patients treated with oxaliplatin-based chemotherapy.
Bahrami A; Amerizadeh F; Hassanian SM; ShahidSales S; Khazaei M; Maftouh M; Ghayour-Mobarhan M; Ferns GA; Avan A
J Cell Physiol; 2018 Mar; 233(3):2193-2201. PubMed ID: 28422287
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenomics and -genetics in colorectal cancer.
Pohl A; Lurje G; Manegold PC; Lenz HJ
Adv Drug Deliv Rev; 2009 May; 61(5):375-80. PubMed ID: 19100300
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy for advanced colorectal cancer. Does the evidence or the doctor have the greater influence?
Munday D
BMJ; 2001 Jan; 322(7280):233. PubMed ID: 11159627
[No Abstract] [Full Text] [Related]
15. Chemoresponsiveness associated with canonical molecular changes in colorectal adenocarcinomas.
Kim JC; Roh SA; Cho DH; Kim TW; Yoon SN; Kim CW; Yu CS; Kim SY; Kim YS
Anticancer Res; 2009 Aug; 29(8):3115-23. PubMed ID: 19661324
[TBL] [Abstract][Full Text] [Related]
16. Mismatch repair deficiency predicts benefit of anti-PD-1 therapy.
Lau E
Lancet Oncol; 2015 Jul; 16(7):e319. PubMed ID: 26062774
[No Abstract] [Full Text] [Related]
17. The role of preoperative chemotherapy in patients with resectable colorectal liver metastases.
Benoist S; Nordlinger B
Ann Surg Oncol; 2009 Sep; 16(9):2385-90. PubMed ID: 19554377
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy for advanced colorectal cancer. Patients need time to reflect on uncertainties surrounding palliative chemotherapy.
Jeffrey DI
BMJ; 2001 Jan; 322(7280):234. PubMed ID: 11159629
[No Abstract] [Full Text] [Related]
19. [Pharmacogenetics and tumor sensitivity of antineoplastic agents. Application to colorectal cancer].
Milano G
Rev Prat; 2008 May; 58(10):1056-9. PubMed ID: 18652401
[TBL] [Abstract][Full Text] [Related]
20. Urokinase-type plasminogen activator is a marker of aggressive phenotype and an independent prognostic factor in mismatch repair-proficient colorectal cancer.
Minoo P; Baker K; Baumhoer D; Terracciano L; Lugli A; Zlobec I
Hum Pathol; 2010 Jan; 41(1):70-8. PubMed ID: 19740518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
